Mu-type opioid receptor (MOR) (MOR)

The mu-type opioid receptor (MOR) is a principal member of the G protein-coupled receptor family and serves as the primary mediator for the analgesic and rewarding effects of both endogenous and exogenous opioids [1]. Located predominantly in the central and peripheral nervous systems, MOR activation inhibits adenylate cyclase activity and modulates ion channel conductance, leading to reduced neuronal excitability [1]. This receptor plays a critical role in the modulation of pain, emotional response, and the reward circuitry, making it a central target for treating acute and chronic pain conditions [2]. However, its overstimulation is also responsible for the development of opioid use disorder and life-threatening respiratory depression [3]. Buprenorphine interacts with MOR as a high-affinity partial agonist, providing a therapeutic "ceiling effect" that reduces the risk of overdose and abuse compared to full agonists like morphine or fentanyl [2, 4]. This pharmacological profile allows buprenorphine to effectively manage opioid withdrawal symptoms and cravings while maintaining a higher safety margin [2]. Furthermore, the receptor's expression in the gastrointestinal tract contributes to side effects such as constipation, which remains a significant clinical challenge [1]. Understanding the structural biology of MOR has led to the development of biased ligands that aim to separate analgesia from respiratory depression [1, 2].

Other names

OPRM1Mu opioid receptorMOPMOR-1Opioid receptor mu 1

Buprenorphine acts as a high-affinity partial agonist at the mu-type opioid receptor, meaning it activates the receptor but produces a sub-maximal response compared to full agonists [2]. It also acts as an antagonist at the kappa-opioid receptor and a weak partial agonist at the delta-opioid receptor [4]. This unique profile results in a ceiling effect for respiratory depression and euphoria, making it effective for treating opioid dependence and pain management [2].